<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-HXULOFAR</identifier><date>2016</date><creator>Martinc, Boštjan</creator><relation>documents/doc/H/URN_NBN_SI_doc-HXULOFAR_001.pdf</relation><relation>documents/doc/H/URN_NBN_SI_doc-HXULOFAR_001.txt</relation><format format_type="issue">2/3</format><format format_type="volume">67</format><format format_type="type">article</format><format format_type="extent">str. 117-126</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">30046503</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-HXULOFAR</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="eng">drug</subject><subject language_type_id="slv">sladkorna bolezen</subject><subject language_type_id="eng">therapy</subject><subject language_type_id="slv">zdravila</subject><subject language_type_id="slv">zdravljenje</subject><title>Novelties in pharmacotherapy of type 2 diabetes</title><title>Novosti v zdravljenju sladkorne bolezni tipa 2</title></Record>